Lista de obras - Luca Moscetti - Dominio Público Uruguay

"Triple positive" early breast cancer: an observational multicenter retrospective analysis of outcome.

scientific article published on 18 February 2016

A Real-World Multicentre Retrospective Study of Paclitaxel-Bevacizumab and Maintenance Therapy as First-Line for HER2-Negative Metastatic Breast Cancer.

artículo científico publicado en 2016

A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study

artículo científico publicado en 2018

A phase II study of cetuximab/irinotecan in patients with heavily pretreated metastatic colorectal cancer: predictive value of early specific toxicities

artículo científico publicado en 2008

A randomised phase II trial of two sequential schedules of docetaxel and cisplatin followed by gemcitabine in patients with advanced non-small-cell lung cancer

artículo científico publicado en 2011

A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience

artículo científico publicado en 2017

Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial.

artículo científico publicado en 2018

Adjuvant aromatase inhibitor therapy in early breast cancer: what factors lead patients to discontinue treatment?

artículo científico publicado en 2015

Ado-trastuzumab emtansine (T-DM1) in HER2+ advanced breast cancer patients: does pretreatment with pertuzumab matter?

artículo científico publicado en 2017

Are All Patients Truly Hormone Receptor Negative?

artículo científico publicado en 2017

Bi-weekly chemotherapy with cisplatin, epirubicin, folinic acid and 5-fluororacil continuous infusion plus g-csf in advanced gastric cancer: a multicentric phase II study

artículo científico publicado en 2005

Body Mass Index and Treatment Outcomes in Metastatic Breast Cancer Patients Treated With Eribulin.

artículo científico publicado en 2015

Body mass index in HER2-negative metastatic breast cancer treated with first-line paclitaxel and bevacizumab.

artículo científico publicado en 2018

Brain metastases from solid tumors: disease outcome according to type of treatment and therapeutic resources of the treating center

artículo científico publicado en 2011

Capecitabine and oxaliplatin in advanced colorectal cancer: a dose-finding study.

artículo científico publicado en 2001

Clinical and molecular predictors of long-term response in HER2 positive metastatic breast cancer patients

artículo científico publicado en 2018

Combinations in the first-line treatment of patients with advanced/metastatic renal cell cancer: regulatory aspects

artículo científico publicado en 2020

Corrigendum: Natural History of Non-Small-Cell Lung Cancer with Bone Metastases.

artículo científico publicado en 2016

Current challenges in HER2-positive breast cancer.

artículo científico publicado en 2015

Differential molecular pathways expression in HER2 positive early breast cancer according to hormone receptor status

scientific article published on 02 January 2019

Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting

artículo científico publicado en 2019

Dose intensity and efficacy of the combination of everolimus and exemestane (EVE/EXE) in a real-world population of hormone receptor-positive (ER+/PgR+), HER2-negative advanced breast cancer (ABC) patients: a multicenter Italian experience.

artículo científico publicado en 2017

ESAS and FACT-B in eribulin-treated metastatic breast cancer patients: a multicenter, prospective and observational study

artículo científico publicado en 2017

Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer

artículo científico publicado en 2013

Efficacy and safety of T-DM1 in the 'common-practice' of HER2+ advanced breast cancer setting: a multicenter study.

artículo científico publicado en 2017

Eribulin in heavily pretreated metastatic breast cancer patients and clinical/biological feature correlations: impact on the practice

artículo científico publicado en 2015

Eribulin mesylate in pretreated breast cancer patients: a multicenter retrospective observational study.

artículo científico publicado en 2014

Fasting glucose and body mass index as predictors of activity in breast cancer patients treated with everolimus-exemestane: The EverExt study

artículo científico publicado en 2017

First-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancer

artículo científico publicado en 2013

Fulvestrant 500 milligrams as endocrine therapy for endocrine sensitive advanced breast cancer patients in the real world: the Ful500 prospective observational trial.

artículo científico publicado en 2017

Gemcitabine and carboplatin for pretreated metastatic breast cancer: the predictive value of immunohistochemically defined subtypes

scientific article published on 17 February 2012

Gemcitabine with or without continuous infusion 5-FU in advanced pancreatic cancer: a randomised phase II trial of the Italian oncology group for clinical research (GOIRC).

artículo científico publicado en 2005

Genomic alterations at the basis of treatment resistance in metastatic breast cancer: clinical applications

artículo científico publicado en 2018

Identification of subgroups of early breast cancer patients at high risk of nonadherence to adjuvant hormone therapy: results of an Italian survey

artículo científico publicado en 2014

Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence

artículo científico publicado en 2020

Impact of gefitinib ('Iressa') treatment on the quality of life of patients with advanced non-small-cell lung cancer

artículo científico publicado en 2005

Long-term outcome of breast cancer patients with pathologic N3a lymph node stage.

artículo científico publicado en 2017

Lymphopenia and clinical outcome of elderly patients treated with sunitinib for metastatic renal cell cancer.

artículo científico publicado en 2014

Maintenance single-agent bevacizumab or observation after first-line chemotherapy in patients with metastatic colorectal cancer: a multicenter retrospective study

scientific article published on 17 February 2013

Mutational Profile of Metastatic Breast Cancer Tissue in Patients Treated with Exemestane Plus Everolimus

artículo científico publicado en 2018

Neoadjuvant Chemotherapy In Triple-Negative Breast Cancer: A Multicentric Retrospective Observational Study In Real-Life Setting.

artículo científico

Neoadjuvant treatments in triple-negative breast cancer patients: where we are now and where we are going

artículo científico publicado en 2018

Optimal tolerability and high efficacy of a modified schedule of lapatinib-capecitabine in advanced breast cancer patients

artículo científico publicado en 2013

Outcomes of HER2-positive early breast cancer patients in the pre-trastuzumab and trastuzumab eras: a real-world multicenter observational analysis. The RETROHER study

artículo científico publicado en 2014

Palbociclib Plus Fulvestrant or Everolimus Plus Exemestane for Pretreated Advanced Breast Cancer with Lobular Histotype in ER+/HER2- Patients: A Propensity Score-Matched Analysis of a Multicenter Retrospective Patient Series

scientific article published on 18 December 2020

Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience

artículo científico publicado en 2018

Predictive Role Of Body Composition Parameters In Operable Breast Cancer Patients Treated With Neoadjuvant Chemotherapy

scientific article published on 12 November 2019

Recurrence risk in small, node-negative, early breast cancer: a multicenter retrospective analysis

artículo científico publicado en 2013

Reply to Kadri Altundag: Do cut-off values of lymph node ratio and presence of perineural invasion affect survival in breast cancer patients with pathologic N3a lymph node stage?

artículo científico publicado en 2017

Rhabdomyolysis from erlotinib: a case report.

artículo científico publicado en 2011

Safety analysis, association with response and previous treatments of everolimus and exemestane in 181 metastatic breast cancer patients: A multicenter Italian experience

artículo científico publicado en 2016

Severe rhabdomyolysis during sunitinib treatment of metastatic renal cell carcinoma. A report of two cases ⬇️

artículo científico publicado el 1 de septiembre de 2010

Spotlight on triptorelin in the treatment of premenopausal women with early-stage breast cancer.

artículo científico publicado en 2018

Standard vs adapted sunitinib regimen in elderly patients with metastatic renal cell cancer: results from a large retrospective analysis.

artículo científico publicado en 2013

T-DM1 and brain metastases: Clinical outcome in HER2-positive metastatic breast cancer

artículo científico publicado en 2018

The unmet need for oncofertility preservation in women: Results of a survey by different oncological specialists in Lazio, Italy

artículo científico publicado en 2019

Triple positive breast cancer: a distinct subtype?

artículo científico publicado en 2014

Up-front chemotherapy and radiation treatment in newly diagnosed nonsmall cell lung cancer with brain metastases: survey by Outcome Research Network for Evaluation of Treatment Results in Oncology

artículo científico publicado en 2007

Use of tyrosine kinase inhibitors in patients with metastatic kidney cancer receiving haemodialysis: a retrospective Italian survey

artículo científico publicado en 2012

Value of KRAS as prognostic or predictive marker in NSCLC: results from the TAILOR trial.

artículo científico publicado en 2015

Lista de obras de Luca Moscetti

"Triple positive" early breast cancer: an observational multicenter retrospective analysis of outcome.

A Real-World Multicentre Retrospective Study of Paclitaxel-Bevacizumab and Maintenance Therapy as First-Line for HER2-Negative Metastatic Breast Cancer.

A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study

A phase II study of cetuximab/irinotecan in patients with heavily pretreated metastatic colorectal cancer: predictive value of early specific toxicities

A randomised phase II trial of two sequential schedules of docetaxel and cisplatin followed by gemcitabine in patients with advanced non-small-cell lung cancer

A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience

Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial.

Adjuvant aromatase inhibitor therapy in early breast cancer: what factors lead patients to discontinue treatment?

Ado-trastuzumab emtansine (T-DM1) in HER2+ advanced breast cancer patients: does pretreatment with pertuzumab matter?

Are All Patients Truly Hormone Receptor Negative?

Bi-weekly chemotherapy with cisplatin, epirubicin, folinic acid and 5-fluororacil continuous infusion plus g-csf in advanced gastric cancer: a multicentric phase II study

Body Mass Index and Treatment Outcomes in Metastatic Breast Cancer Patients Treated With Eribulin.

Body mass index in HER2-negative metastatic breast cancer treated with first-line paclitaxel and bevacizumab.

Brain metastases from solid tumors: disease outcome according to type of treatment and therapeutic resources of the treating center

Capecitabine and oxaliplatin in advanced colorectal cancer: a dose-finding study.

Clinical and molecular predictors of long-term response in HER2 positive metastatic breast cancer patients

Combinations in the first-line treatment of patients with advanced/metastatic renal cell cancer: regulatory aspects

Corrigendum: Natural History of Non-Small-Cell Lung Cancer with Bone Metastases.

Current challenges in HER2-positive breast cancer.

Differential molecular pathways expression in HER2 positive early breast cancer according to hormone receptor status

Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting

Dose intensity and efficacy of the combination of everolimus and exemestane (EVE/EXE) in a real-world population of hormone receptor-positive (ER+/PgR+), HER2-negative advanced breast cancer (ABC) patients: a multicenter Italian experience.

ESAS and FACT-B in eribulin-treated metastatic breast cancer patients: a multicenter, prospective and observational study

Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer

Efficacy and safety of T-DM1 in the 'common-practice' of HER2+ advanced breast cancer setting: a multicenter study.

Eribulin in heavily pretreated metastatic breast cancer patients and clinical/biological feature correlations: impact on the practice

Eribulin mesylate in pretreated breast cancer patients: a multicenter retrospective observational study.

Fasting glucose and body mass index as predictors of activity in breast cancer patients treated with everolimus-exemestane: The EverExt study

First-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancer

Fulvestrant 500 milligrams as endocrine therapy for endocrine sensitive advanced breast cancer patients in the real world: the Ful500 prospective observational trial.

Gemcitabine and carboplatin for pretreated metastatic breast cancer: the predictive value of immunohistochemically defined subtypes

Gemcitabine with or without continuous infusion 5-FU in advanced pancreatic cancer: a randomised phase II trial of the Italian oncology group for clinical research (GOIRC).

Genomic alterations at the basis of treatment resistance in metastatic breast cancer: clinical applications

Identification of subgroups of early breast cancer patients at high risk of nonadherence to adjuvant hormone therapy: results of an Italian survey

Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence

Impact of gefitinib ('Iressa') treatment on the quality of life of patients with advanced non-small-cell lung cancer

Long-term outcome of breast cancer patients with pathologic N3a lymph node stage.

Lymphopenia and clinical outcome of elderly patients treated with sunitinib for metastatic renal cell cancer.

Maintenance single-agent bevacizumab or observation after first-line chemotherapy in patients with metastatic colorectal cancer: a multicenter retrospective study

Mutational Profile of Metastatic Breast Cancer Tissue in Patients Treated with Exemestane Plus Everolimus

Neoadjuvant Chemotherapy In Triple-Negative Breast Cancer: A Multicentric Retrospective Observational Study In Real-Life Setting.

Neoadjuvant treatments in triple-negative breast cancer patients: where we are now and where we are going

Optimal tolerability and high efficacy of a modified schedule of lapatinib-capecitabine in advanced breast cancer patients

Outcomes of HER2-positive early breast cancer patients in the pre-trastuzumab and trastuzumab eras: a real-world multicenter observational analysis. The RETROHER study

Palbociclib Plus Fulvestrant or Everolimus Plus Exemestane for Pretreated Advanced Breast Cancer with Lobular Histotype in ER+/HER2- Patients: A Propensity Score-Matched Analysis of a Multicenter Retrospective Patient Series

Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience

Predictive Role Of Body Composition Parameters In Operable Breast Cancer Patients Treated With Neoadjuvant Chemotherapy

Recurrence risk in small, node-negative, early breast cancer: a multicenter retrospective analysis

Reply to Kadri Altundag: Do cut-off values of lymph node ratio and presence of perineural invasion affect survival in breast cancer patients with pathologic N3a lymph node stage?

Rhabdomyolysis from erlotinib: a case report.

Safety analysis, association with response and previous treatments of everolimus and exemestane in 181 metastatic breast cancer patients: A multicenter Italian experience

Severe rhabdomyolysis during sunitinib treatment of metastatic renal cell carcinoma. A report of two cases ⬇️

Spotlight on triptorelin in the treatment of premenopausal women with early-stage breast cancer.

Standard vs adapted sunitinib regimen in elderly patients with metastatic renal cell cancer: results from a large retrospective analysis.

T-DM1 and brain metastases: Clinical outcome in HER2-positive metastatic breast cancer

The unmet need for oncofertility preservation in women: Results of a survey by different oncological specialists in Lazio, Italy

Triple positive breast cancer: a distinct subtype?

Up-front chemotherapy and radiation treatment in newly diagnosed nonsmall cell lung cancer with brain metastases: survey by Outcome Research Network for Evaluation of Treatment Results in Oncology

Use of tyrosine kinase inhibitors in patients with metastatic kidney cancer receiving haemodialysis: a retrospective Italian survey

Value of KRAS as prognostic or predictive marker in NSCLC: results from the TAILOR trial.